GB201910729D0 - Bevacizumab concentration as an indicator of treatment response and overall survival - Google Patents

Bevacizumab concentration as an indicator of treatment response and overall survival

Info

Publication number
GB201910729D0
GB201910729D0 GBGB1910729.1A GB201910729A GB201910729D0 GB 201910729 D0 GB201910729 D0 GB 201910729D0 GB 201910729 A GB201910729 A GB 201910729A GB 201910729 D0 GB201910729 D0 GB 201910729D0
Authority
GB
United Kingdom
Prior art keywords
indicator
overall survival
treatment response
bevacizumab concentration
bevacizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1910729.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aenorasis Commercial Co Of Pharmaceutical And Medical Products And Machines SA
Original Assignee
Aenorasis Commercial Co Of Pharmaceutical And Medical Products And Machines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aenorasis Commercial Co Of Pharmaceutical And Medical Products And Machines SA filed Critical Aenorasis Commercial Co Of Pharmaceutical And Medical Products And Machines SA
Publication of GB201910729D0 publication Critical patent/GB201910729D0/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1910729.1A 2019-06-25 2019-07-26 Bevacizumab concentration as an indicator of treatment response and overall survival Ceased GB201910729D0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20190100279A GR1009946B (en) 2019-06-25 2019-06-25 Bevacizumab concentration as an indication of treatement response and overall survival

Publications (1)

Publication Number Publication Date
GB201910729D0 true GB201910729D0 (en) 2019-09-11

Family

ID=67990502

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1910729.1A Ceased GB201910729D0 (en) 2019-06-25 2019-07-26 Bevacizumab concentration as an indicator of treatment response and overall survival

Country Status (2)

Country Link
GB (1) GB201910729D0 (en)
GR (1) GR1009946B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891047A1 (en) * 2010-01-19 2011-07-18 F. Hoffmann-La Roche Ag Tumor tissue based biomarkers for bevacizumab combination therapies
CN103140761B (en) * 2010-07-19 2015-11-25 霍夫曼-拉罗奇有限公司 Bevacizumab combination treatment is used for the treatment of the blood plasma biomarker of cancer of pancreas

Also Published As

Publication number Publication date
GR1009946B (en) 2021-03-04
GR20190100279A (en) 2021-01-19

Similar Documents

Publication Publication Date Title
IL277648A (en) Therapeutic microbiota for the treatment and/or prevention of food allergy
EP3349783C0 (en) Compositions and methods relating to the treatment of diseases
HK1257739A1 (en) Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
EP3694411A4 (en) Breath sensor apparatus and methods of use
IN2015DN02032A (en)
HK1245658A1 (en) Nutritional composition useful in the treatment of ibd patients
SG11201703704PA (en) Diagnosis and treatment of incipient diabetes
EP3706736A4 (en) Ash1l degraders and methods of treatment therewith
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
SG10201908584SA (en) Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease
ZA201902873B (en) Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
EP3691646A4 (en) Inhalable composition of clofazimine and methods of use
EA201790699A1 (en) STABILIZED DERIVATIVES OF ADRENOMEDULLINE AND THEIR APPLICATION
IL272121A (en) Composition and methods for the treatment of myopia
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
AU2017267955B2 (en) Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
GB201511799D0 (en) Composition and methods of treatment
ZA201705400B (en) Compositions containing arsenic and their use in methods of treatment
MX2015001648A (en) Compositions comprising spicamycin derivatives and methods of use thereof.
ZA201808565B (en) An edible composition for reducing the digestion or absorption of the harmful/toxic substance
GB201910729D0 (en) Bevacizumab concentration as an indicator of treatment response and overall survival
EP3377054A4 (en) Homotaurine-enriched compositions and methods of use for animal health
GB201605127D0 (en) Composition and methods of treatment
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
ZA201905343B (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)